TY - CHAP A1 - Bünder, Tobias A1 - Rathert, Nikolas A1 - Mair, Johanna A2 - George, Gerard A2 - Haas, Martine A2 - Joshi, Havovi A2 - McGahan, Anita A2 - Tracey, Paul T1 - Understanding firm- and field-level change toward sustainable development: insights from the pharmaceutical industry and access to medicines, 1960‒2020 T2 - Handbook on the Business of Sustainability N2 - Insufficient access to medicines is a persistent global problem that affects billions of people in low- and middle-income countries. In this chapter, we use access to medicines as a case to understand how business can become instrumental in making progress on persistent and global problems we associate with sustainable development. We examine the emergence and evolution of access to medicines as a mandate for the pharmaceutical industry to contribute to sustainable development. More specifically, we trace the historical developments of corporate social initiatives in the industry and revisit existing research on access to medicines in management and related fields. We then introduce three distinct analytical perspectives - field emergence and change, firm heterogeneity, organizational processes - to examine access to medicine, expose managerial challenges and offer a research agenda that helps to advance research on access to medicines and, more generally, on corporate efforts to address pressing global problems subsumed under the Sustainable Development Goals. Y1 - 2022 UR - https://opus4.kobv.de/opus4-hsog/frontdoor/index/index/docId/4981 SN - 9781839105333 U6 - https://doi.org/10.4337/9781839105340.00025 SP - 300 EP - 319 PB - Edward Elgar CY - Cheltenham ER -